Entity Metadata

• Generic Name: Narasin
• Trade Names: Monteban, Maxiban
• Active Ingredient: Polyether ionophore produced by Streptomyces aureofaciens
• Drug Class: Anticoccidial > Polyether Ionophore
• Commercial Importance: Critical
• India Relevance: 3 day withdrawal
• Status: Permitted (subject to statutory withdrawal period)

Identity

Narasin is an active therapeutic medicine and polyether ionophore used within the poultry sector to target specific parasitic infections.

Overview

Narasin is a critical therapeutic anticoccidial used in the Indian poultry industry. Produced by the fermentation of Streptomyces aureofaciens, it is specifically indicated for the prevention and treatment of Coccidiosis, targeting the asexual stages of Eimeria species. To ensure compliance with food safety and regulatory standards, its administration requires a statutory withdrawal period of 3 days. It shares contraindications with other ionophores and must not be used concurrently with pleuromutilins.

Structured Facts

Indications

Coccidiosis, Eimeria species (E. acervulina, E. brunetti, E. maxima, E. necatrix, E. tenella).

Mechanism of Action

Alters transmembrane monovalent ion movement. Chemically, it acts as a derivative of salinomycin with an additional methyl group.

Dosage

54-72 g/ton (monotherapy); 40-50 g/ton (when combined with nicarbazin as Maxiban).

Administration Route

Feed.

Withdrawal Period

3 Days (India); 0 days (FDA monotherapy), 1 day (Maxiban).

Contraindications

Contraindicated with pleuromutilins (tiamulin). Toxic to laying hens and turkeys/equine species.

Adverse Effects

Causes severe skeletal and myocardial necrosis if administered alongside CYP3A inhibitors.

Quantitative Data

• Dose: 54-72 g/ton (monotherapy); 40-50 g/ton (with nicarbazin)
• Withdrawal: 3 Days

Relationships

• Target Diseases: Coccidiosis (Eimeria species).
• Related Medicines: Salinomycin (chemical precursor), Nicarbazin (synergistic combination).
• Drug Interactions: Lethal interaction with tiamulin (pleuromutilins) due to Cytochrome P450 pathway competition.

Evidence

• Source: India Poultry Knowledge Inventory, India Poultry Knowledge Inventory and Master Management Guide, Poultry Medicine Research Plan
• Evidence Strength: High

References

• India Poultry Knowledge Inventory
• India Poultry Knowledge Inventory and Master Management Guide
• Poultry Disease and Health Management Compendium
• Poultry Medicine Research Plan

Missing Information

Exact chemical formula, administration duration, storage conditions, precise page numbers.

Schema Coverage

Identity: Complete Structured Facts: Partial Quantitative Data: Partial Relationships: Partial Evidence: Partial References: Complete Overall Completeness: 75%